Cancer Discovery

Despite Risk of Breast Cancer, Few Men Undergo Genetic Tests, Study Finds

Cancer is one of the leading causes of death among Americans. At least 10 percent of cancers are caused by inherited mutations in genes such as BRCA1 and BRCA2. Parents with the cancer gene mutation have a 50 percent chance of passing it on to a son or daughter. It’s well-known that women with BRCA are at a very high risk for breast and ovarian cancer. Less known is the
Biotechnology cancer

New Clinical Trial Combines Two Methods to Defeat Ovarian Cancer

New clinical trial offers combination therapy to directly kill cancer cells and teach the immune system to keep them from coming back. Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, hopes her new clinical trial will change this outcome. Adams recently opened a clinical trial at The University of New Mexico Comprehensive Cancer Center to test a new approach to
Biotechnology cancer

Study Identifies Subtype of Triple Negative Breast Cancer That Responds Better to Chemotherapy

Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined “BRCA deficient” subtype experienced better survival with chemotherapy. The study was published on Dec. 13 in PLOS Medicine. Triple negative breast cancer (TNBC) disproportionately affects younger women and women of African ancestry, contributing to health disparities. In the era of personalized cancer therapy,